nodes	percent_of_prediction	percent_of_DWPC	metapath
Dicyclomine—CYP1A1—breast cancer	0.423	1	CbGaD
Dicyclomine—CYP1A1—Toremifene—breast cancer	0.173	0.733	CbGbCtD
Dicyclomine—CYP1A1—Tamoxifen—breast cancer	0.0631	0.268	CbGbCtD
Dicyclomine—CHRM3—muscle of abdomen—breast cancer	0.00381	0.437	CbGeAlD
Dicyclomine—CYP1A1—nipple—breast cancer	0.000505	0.0579	CbGeAlD
Dicyclomine—CHRM1—female reproductive system—breast cancer	0.000377	0.0432	CbGeAlD
Dicyclomine—CHRM3—adipose tissue—breast cancer	0.000367	0.0421	CbGeAlD
Dicyclomine—CHRM2—endocrine gland—breast cancer	0.00035	0.0402	CbGeAlD
Dicyclomine—CYP1A1—epithelium—breast cancer	0.00034	0.039	CbGeAlD
Dicyclomine—CHRM3—female reproductive system—breast cancer	0.000337	0.0387	CbGeAlD
Dicyclomine—CYP1A1—skin of body—breast cancer	0.000323	0.0371	CbGeAlD
Dicyclomine—CHRM1—endocrine gland—breast cancer	0.000319	0.0366	CbGeAlD
Dicyclomine—CHRM3—female gonad—breast cancer	0.000307	0.0352	CbGeAlD
Dicyclomine—CHRM3—endocrine gland—breast cancer	0.000285	0.0327	CbGeAlD
Dicyclomine—CYP1A1—uterus—breast cancer	0.000281	0.0322	CbGeAlD
Dicyclomine—CYP1A1—adipose tissue—breast cancer	0.000275	0.0315	CbGeAlD
Dicyclomine—CYP1A1—female reproductive system—breast cancer	0.000252	0.0289	CbGeAlD
Dicyclomine—CYP1A1—female gonad—breast cancer	0.00023	0.0263	CbGeAlD
Dicyclomine—CYP1A1—endocrine gland—breast cancer	0.000214	0.0245	CbGeAlD
Dicyclomine—CYP1A1—lymph node—breast cancer	0.000148	0.0169	CbGeAlD
Dicyclomine—Dyspnoea—Paclitaxel—breast cancer	0.000115	0.000465	CcSEcCtD
Dicyclomine—Headache—Thiotepa—breast cancer	0.000115	0.000464	CcSEcCtD
Dicyclomine—Somnolence—Paclitaxel—breast cancer	0.000115	0.000463	CcSEcCtD
Dicyclomine—Palpitations—Capecitabine—breast cancer	0.000115	0.000463	CcSEcCtD
Dicyclomine—Loss of consciousness—Capecitabine—breast cancer	0.000114	0.000461	CcSEcCtD
Dicyclomine—Nausea—Vinorelbine—breast cancer	0.000114	0.00046	CcSEcCtD
Dicyclomine—Dyspepsia—Paclitaxel—breast cancer	0.000114	0.000459	CcSEcCtD
Dicyclomine—Asthenia—Mitoxantrone—breast cancer	0.000114	0.000458	CcSEcCtD
Dicyclomine—Asthenia—Irinotecan—breast cancer	0.000114	0.000458	CcSEcCtD
Dicyclomine—Decreased appetite—Paclitaxel—breast cancer	0.000113	0.000453	CcSEcCtD
Dicyclomine—Hypertension—Capecitabine—breast cancer	0.000112	0.000452	CcSEcCtD
Dicyclomine—Hypersensitivity—Fluorouracil—breast cancer	0.000112	0.000451	CcSEcCtD
Dicyclomine—Dry mouth—Docetaxel—breast cancer	0.000112	0.000451	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Paclitaxel—breast cancer	0.000112	0.00045	CcSEcCtD
Dicyclomine—Fatigue—Paclitaxel—breast cancer	0.000112	0.000449	CcSEcCtD
Dicyclomine—Asthenia—Gemcitabine—breast cancer	0.000111	0.000447	CcSEcCtD
Dicyclomine—Constipation—Paclitaxel—breast cancer	0.000111	0.000446	CcSEcCtD
Dicyclomine—Pain—Paclitaxel—breast cancer	0.000111	0.000446	CcSEcCtD
Dicyclomine—Confusional state—Docetaxel—breast cancer	0.000111	0.000445	CcSEcCtD
Dicyclomine—Oedema—Docetaxel—breast cancer	0.00011	0.000442	CcSEcCtD
Dicyclomine—Anaphylactic shock—Docetaxel—breast cancer	0.00011	0.000442	CcSEcCtD
Dicyclomine—Discomfort—Capecitabine—breast cancer	0.000109	0.000441	CcSEcCtD
Dicyclomine—Pruritus—Gemcitabine—breast cancer	0.000109	0.00044	CcSEcCtD
Dicyclomine—Nausea—Thiotepa—breast cancer	0.000109	0.00044	CcSEcCtD
Dicyclomine—Dry mouth—Capecitabine—breast cancer	0.000108	0.000436	CcSEcCtD
Dicyclomine—Shock—Docetaxel—breast cancer	0.000108	0.000435	CcSEcCtD
Dicyclomine—Nervous system disorder—Docetaxel—breast cancer	0.000108	0.000433	CcSEcCtD
Dicyclomine—Pruritus—Fluorouracil—breast cancer	0.000108	0.000433	CcSEcCtD
Dicyclomine—Drowsiness—Doxorubicin—breast cancer	0.000107	0.000432	CcSEcCtD
Dicyclomine—Confusional state—Capecitabine—breast cancer	0.000107	0.000431	CcSEcCtD
Dicyclomine—Tachycardia—Docetaxel—breast cancer	0.000107	0.000431	CcSEcCtD
Dicyclomine—Feeling abnormal—Paclitaxel—breast cancer	0.000107	0.000429	CcSEcCtD
Dicyclomine—Oedema—Capecitabine—breast cancer	0.000106	0.000428	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Paclitaxel—breast cancer	0.000106	0.000426	CcSEcCtD
Dicyclomine—Dizziness—Irinotecan—breast cancer	0.000105	0.000423	CcSEcCtD
Dicyclomine—Anorexia—Docetaxel—breast cancer	0.000105	0.000421	CcSEcCtD
Dicyclomine—Shock—Capecitabine—breast cancer	0.000104	0.000421	CcSEcCtD
Dicyclomine—Nervous system disorder—Capecitabine—breast cancer	0.000104	0.000419	CcSEcCtD
Dicyclomine—Eye disorder—Methotrexate—breast cancer	0.000104	0.000419	CcSEcCtD
Dicyclomine—Tachycardia—Capecitabine—breast cancer	0.000104	0.000417	CcSEcCtD
Dicyclomine—Hypoaesthesia—Epirubicin—breast cancer	0.000104	0.000417	CcSEcCtD
Dicyclomine—Cardiac disorder—Methotrexate—breast cancer	0.000103	0.000416	CcSEcCtD
Dicyclomine—Urticaria—Paclitaxel—breast cancer	0.000103	0.000414	CcSEcCtD
Dicyclomine—Abdominal pain—Paclitaxel—breast cancer	0.000102	0.000412	CcSEcCtD
Dicyclomine—Anorexia—Capecitabine—breast cancer	0.000101	0.000408	CcSEcCtD
Dicyclomine—Vomiting—Mitoxantrone—breast cancer	0.000101	0.000406	CcSEcCtD
Dicyclomine—Vomiting—Irinotecan—breast cancer	0.000101	0.000406	CcSEcCtD
Dicyclomine—Immune system disorder—Methotrexate—breast cancer	0.000101	0.000405	CcSEcCtD
Dicyclomine—Dizziness—Fluorouracil—breast cancer	0.000101	0.000405	CcSEcCtD
Dicyclomine—Mediastinal disorder—Methotrexate—breast cancer	0.0001	0.000404	CcSEcCtD
Dicyclomine—Rash—Irinotecan—breast cancer	0.0001	0.000403	CcSEcCtD
Dicyclomine—Rash—Mitoxantrone—breast cancer	0.0001	0.000403	CcSEcCtD
Dicyclomine—Dermatitis—Mitoxantrone—breast cancer	0.0001	0.000403	CcSEcCtD
Dicyclomine—Dermatitis—Irinotecan—breast cancer	0.0001	0.000403	CcSEcCtD
Dicyclomine—Headache—Mitoxantrone—breast cancer	9.94e-05	0.0004	CcSEcCtD
Dicyclomine—Headache—Irinotecan—breast cancer	9.94e-05	0.0004	CcSEcCtD
Dicyclomine—Insomnia—Docetaxel—breast cancer	9.92e-05	0.0004	CcSEcCtD
Dicyclomine—Paraesthesia—Docetaxel—breast cancer	9.85e-05	0.000397	CcSEcCtD
Dicyclomine—Vomiting—Gemcitabine—breast cancer	9.83e-05	0.000396	CcSEcCtD
Dicyclomine—Dyspnoea—Docetaxel—breast cancer	9.78e-05	0.000394	CcSEcCtD
Dicyclomine—Somnolence—Docetaxel—breast cancer	9.75e-05	0.000393	CcSEcCtD
Dicyclomine—Mental disorder—Methotrexate—breast cancer	9.75e-05	0.000393	CcSEcCtD
Dicyclomine—Rash—Gemcitabine—breast cancer	9.75e-05	0.000392	CcSEcCtD
Dicyclomine—Dermatitis—Gemcitabine—breast cancer	9.74e-05	0.000392	CcSEcCtD
Dicyclomine—Eye disorder—Epirubicin—breast cancer	9.73e-05	0.000392	CcSEcCtD
Dicyclomine—Erythema—Methotrexate—breast cancer	9.69e-05	0.00039	CcSEcCtD
Dicyclomine—Headache—Gemcitabine—breast cancer	9.68e-05	0.00039	CcSEcCtD
Dicyclomine—Cardiac disorder—Epirubicin—breast cancer	9.67e-05	0.000389	CcSEcCtD
Dicyclomine—Vomiting—Fluorouracil—breast cancer	9.66e-05	0.000389	CcSEcCtD
Dicyclomine—Dyspepsia—Docetaxel—breast cancer	9.66e-05	0.000389	CcSEcCtD
Dicyclomine—Insomnia—Capecitabine—breast cancer	9.61e-05	0.000387	CcSEcCtD
Dicyclomine—Hypoaesthesia—Doxorubicin—breast cancer	9.59e-05	0.000386	CcSEcCtD
Dicyclomine—Rash—Fluorouracil—breast cancer	9.58e-05	0.000386	CcSEcCtD
Dicyclomine—Dermatitis—Fluorouracil—breast cancer	9.57e-05	0.000386	CcSEcCtD
Dicyclomine—Paraesthesia—Capecitabine—breast cancer	9.54e-05	0.000384	CcSEcCtD
Dicyclomine—Decreased appetite—Docetaxel—breast cancer	9.54e-05	0.000384	CcSEcCtD
Dicyclomine—Hypersensitivity—Paclitaxel—breast cancer	9.54e-05	0.000384	CcSEcCtD
Dicyclomine—Headache—Fluorouracil—breast cancer	9.52e-05	0.000383	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Docetaxel—breast cancer	9.47e-05	0.000381	CcSEcCtD
Dicyclomine—Dyspnoea—Capecitabine—breast cancer	9.47e-05	0.000381	CcSEcCtD
Dicyclomine—Fatigue—Docetaxel—breast cancer	9.46e-05	0.000381	CcSEcCtD
Dicyclomine—Nausea—Mitoxantrone—breast cancer	9.43e-05	0.00038	CcSEcCtD
Dicyclomine—Nausea—Irinotecan—breast cancer	9.43e-05	0.00038	CcSEcCtD
Dicyclomine—Immune system disorder—Epirubicin—breast cancer	9.41e-05	0.000379	CcSEcCtD
Dicyclomine—Mediastinal disorder—Epirubicin—breast cancer	9.39e-05	0.000378	CcSEcCtD
Dicyclomine—Constipation—Docetaxel—breast cancer	9.38e-05	0.000378	CcSEcCtD
Dicyclomine—Pain—Docetaxel—breast cancer	9.38e-05	0.000378	CcSEcCtD
Dicyclomine—Dyspepsia—Capecitabine—breast cancer	9.35e-05	0.000376	CcSEcCtD
Dicyclomine—Asthenia—Paclitaxel—breast cancer	9.29e-05	0.000374	CcSEcCtD
Dicyclomine—Decreased appetite—Capecitabine—breast cancer	9.23e-05	0.000372	CcSEcCtD
Dicyclomine—Nausea—Gemcitabine—breast cancer	9.18e-05	0.00037	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Capecitabine—breast cancer	9.17e-05	0.000369	CcSEcCtD
Dicyclomine—Fatigue—Capecitabine—breast cancer	9.16e-05	0.000369	CcSEcCtD
Dicyclomine—Pruritus—Paclitaxel—breast cancer	9.16e-05	0.000369	CcSEcCtD
Dicyclomine—Vision blurred—Methotrexate—breast cancer	9.13e-05	0.000368	CcSEcCtD
Dicyclomine—Mental disorder—Epirubicin—breast cancer	9.12e-05	0.000367	CcSEcCtD
Dicyclomine—Pain—Capecitabine—breast cancer	9.08e-05	0.000366	CcSEcCtD
Dicyclomine—Constipation—Capecitabine—breast cancer	9.08e-05	0.000366	CcSEcCtD
Dicyclomine—Erythema—Epirubicin—breast cancer	9.07e-05	0.000365	CcSEcCtD
Dicyclomine—Feeling abnormal—Docetaxel—breast cancer	9.04e-05	0.000364	CcSEcCtD
Dicyclomine—Nausea—Fluorouracil—breast cancer	9.03e-05	0.000364	CcSEcCtD
Dicyclomine—Eye disorder—Doxorubicin—breast cancer	9.01e-05	0.000363	CcSEcCtD
Dicyclomine—Ill-defined disorder—Methotrexate—breast cancer	8.99e-05	0.000362	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Docetaxel—breast cancer	8.97e-05	0.000361	CcSEcCtD
Dicyclomine—Cardiac disorder—Doxorubicin—breast cancer	8.94e-05	0.00036	CcSEcCtD
Dicyclomine—Tension—Epirubicin—breast cancer	8.9e-05	0.000358	CcSEcCtD
Dicyclomine—Nervousness—Epirubicin—breast cancer	8.81e-05	0.000355	CcSEcCtD
Dicyclomine—Feeling abnormal—Capecitabine—breast cancer	8.75e-05	0.000352	CcSEcCtD
Dicyclomine—Malaise—Methotrexate—breast cancer	8.74e-05	0.000352	CcSEcCtD
Dicyclomine—Immune system disorder—Doxorubicin—breast cancer	8.7e-05	0.00035	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Capecitabine—breast cancer	8.69e-05	0.00035	CcSEcCtD
Dicyclomine—Mediastinal disorder—Doxorubicin—breast cancer	8.68e-05	0.00035	CcSEcCtD
Dicyclomine—Abdominal pain—Docetaxel—breast cancer	8.67e-05	0.000349	CcSEcCtD
Dicyclomine—Dizziness—Paclitaxel—breast cancer	8.56e-05	0.000345	CcSEcCtD
Dicyclomine—Vision blurred—Epirubicin—breast cancer	8.54e-05	0.000344	CcSEcCtD
Dicyclomine—Mental disorder—Doxorubicin—breast cancer	8.44e-05	0.00034	CcSEcCtD
Dicyclomine—Urticaria—Capecitabine—breast cancer	8.44e-05	0.00034	CcSEcCtD
Dicyclomine—Ill-defined disorder—Epirubicin—breast cancer	8.41e-05	0.000339	CcSEcCtD
Dicyclomine—Abdominal pain—Capecitabine—breast cancer	8.4e-05	0.000338	CcSEcCtD
Dicyclomine—Erythema—Doxorubicin—breast cancer	8.39e-05	0.000338	CcSEcCtD
Dicyclomine—Agitation—Epirubicin—breast cancer	8.33e-05	0.000335	CcSEcCtD
Dicyclomine—Tension—Doxorubicin—breast cancer	8.23e-05	0.000331	CcSEcCtD
Dicyclomine—Vomiting—Paclitaxel—breast cancer	8.23e-05	0.000331	CcSEcCtD
Dicyclomine—Malaise—Epirubicin—breast cancer	8.18e-05	0.000329	CcSEcCtD
Dicyclomine—Rash—Paclitaxel—breast cancer	8.16e-05	0.000329	CcSEcCtD
Dicyclomine—Dermatitis—Paclitaxel—breast cancer	8.15e-05	0.000328	CcSEcCtD
Dicyclomine—Discomfort—Methotrexate—breast cancer	8.15e-05	0.000328	CcSEcCtD
Dicyclomine—Nervousness—Doxorubicin—breast cancer	8.15e-05	0.000328	CcSEcCtD
Dicyclomine—Syncope—Epirubicin—breast cancer	8.13e-05	0.000327	CcSEcCtD
Dicyclomine—Headache—Paclitaxel—breast cancer	8.11e-05	0.000326	CcSEcCtD
Dicyclomine—Hypersensitivity—Docetaxel—breast cancer	8.08e-05	0.000325	CcSEcCtD
Dicyclomine—Palpitations—Epirubicin—breast cancer	8.01e-05	0.000323	CcSEcCtD
Dicyclomine—Confusional state—Methotrexate—breast cancer	7.97e-05	0.000321	CcSEcCtD
Dicyclomine—Loss of consciousness—Epirubicin—breast cancer	7.97e-05	0.000321	CcSEcCtD
Dicyclomine—Anaphylactic shock—Methotrexate—breast cancer	7.91e-05	0.000318	CcSEcCtD
Dicyclomine—Vision blurred—Doxorubicin—breast cancer	7.91e-05	0.000318	CcSEcCtD
Dicyclomine—Asthenia—Docetaxel—breast cancer	7.87e-05	0.000317	CcSEcCtD
Dicyclomine—Hypertension—Epirubicin—breast cancer	7.83e-05	0.000315	CcSEcCtD
Dicyclomine—Hypersensitivity—Capecitabine—breast cancer	7.83e-05	0.000315	CcSEcCtD
Dicyclomine—Ill-defined disorder—Doxorubicin—breast cancer	7.78e-05	0.000313	CcSEcCtD
Dicyclomine—Pruritus—Docetaxel—breast cancer	7.76e-05	0.000313	CcSEcCtD
Dicyclomine—Nervous system disorder—Methotrexate—breast cancer	7.75e-05	0.000312	CcSEcCtD
Dicyclomine—Agitation—Doxorubicin—breast cancer	7.71e-05	0.00031	CcSEcCtD
Dicyclomine—Nausea—Paclitaxel—breast cancer	7.69e-05	0.00031	CcSEcCtD
Dicyclomine—Discomfort—Epirubicin—breast cancer	7.63e-05	0.000307	CcSEcCtD
Dicyclomine—Asthenia—Capecitabine—breast cancer	7.62e-05	0.000307	CcSEcCtD
Dicyclomine—Malaise—Doxorubicin—breast cancer	7.57e-05	0.000305	CcSEcCtD
Dicyclomine—Dry mouth—Epirubicin—breast cancer	7.55e-05	0.000304	CcSEcCtD
Dicyclomine—Anorexia—Methotrexate—breast cancer	7.54e-05	0.000303	CcSEcCtD
Dicyclomine—Syncope—Doxorubicin—breast cancer	7.52e-05	0.000303	CcSEcCtD
Dicyclomine—Pruritus—Capecitabine—breast cancer	7.51e-05	0.000303	CcSEcCtD
Dicyclomine—Confusional state—Epirubicin—breast cancer	7.46e-05	0.0003	CcSEcCtD
Dicyclomine—Palpitations—Doxorubicin—breast cancer	7.41e-05	0.000299	CcSEcCtD
Dicyclomine—Anaphylactic shock—Epirubicin—breast cancer	7.4e-05	0.000298	CcSEcCtD
Dicyclomine—Oedema—Epirubicin—breast cancer	7.4e-05	0.000298	CcSEcCtD
Dicyclomine—Loss of consciousness—Doxorubicin—breast cancer	7.37e-05	0.000297	CcSEcCtD
Dicyclomine—Shock—Epirubicin—breast cancer	7.28e-05	0.000293	CcSEcCtD
Dicyclomine—Nervous system disorder—Epirubicin—breast cancer	7.26e-05	0.000292	CcSEcCtD
Dicyclomine—Dizziness—Docetaxel—breast cancer	7.25e-05	0.000292	CcSEcCtD
Dicyclomine—Hypertension—Doxorubicin—breast cancer	7.24e-05	0.000292	CcSEcCtD
Dicyclomine—Tachycardia—Epirubicin—breast cancer	7.22e-05	0.000291	CcSEcCtD
Dicyclomine—Insomnia—Methotrexate—breast cancer	7.15e-05	0.000288	CcSEcCtD
Dicyclomine—Paraesthesia—Methotrexate—breast cancer	7.1e-05	0.000286	CcSEcCtD
Dicyclomine—Discomfort—Doxorubicin—breast cancer	7.06e-05	0.000284	CcSEcCtD
Dicyclomine—Anorexia—Epirubicin—breast cancer	7.05e-05	0.000284	CcSEcCtD
Dicyclomine—Dyspnoea—Methotrexate—breast cancer	7.05e-05	0.000284	CcSEcCtD
Dicyclomine—Somnolence—Methotrexate—breast cancer	7.03e-05	0.000283	CcSEcCtD
Dicyclomine—Dizziness—Capecitabine—breast cancer	7.02e-05	0.000283	CcSEcCtD
Dicyclomine—Dry mouth—Doxorubicin—breast cancer	6.98e-05	0.000281	CcSEcCtD
Dicyclomine—Vomiting—Docetaxel—breast cancer	6.98e-05	0.000281	CcSEcCtD
Dicyclomine—Dyspepsia—Methotrexate—breast cancer	6.96e-05	0.00028	CcSEcCtD
Dicyclomine—Rash—Docetaxel—breast cancer	6.92e-05	0.000279	CcSEcCtD
Dicyclomine—Dermatitis—Docetaxel—breast cancer	6.91e-05	0.000278	CcSEcCtD
Dicyclomine—Confusional state—Doxorubicin—breast cancer	6.9e-05	0.000278	CcSEcCtD
Dicyclomine—Decreased appetite—Methotrexate—breast cancer	6.87e-05	0.000277	CcSEcCtD
Dicyclomine—Headache—Docetaxel—breast cancer	6.87e-05	0.000277	CcSEcCtD
Dicyclomine—Anaphylactic shock—Doxorubicin—breast cancer	6.85e-05	0.000276	CcSEcCtD
Dicyclomine—Oedema—Doxorubicin—breast cancer	6.85e-05	0.000276	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Methotrexate—breast cancer	6.83e-05	0.000275	CcSEcCtD
Dicyclomine—Fatigue—Methotrexate—breast cancer	6.82e-05	0.000274	CcSEcCtD
Dicyclomine—Pain—Methotrexate—breast cancer	6.76e-05	0.000272	CcSEcCtD
Dicyclomine—Vomiting—Capecitabine—breast cancer	6.75e-05	0.000272	CcSEcCtD
Dicyclomine—Shock—Doxorubicin—breast cancer	6.74e-05	0.000271	CcSEcCtD
Dicyclomine—Nervous system disorder—Doxorubicin—breast cancer	6.71e-05	0.00027	CcSEcCtD
Dicyclomine—Rash—Capecitabine—breast cancer	6.7e-05	0.00027	CcSEcCtD
Dicyclomine—Insomnia—Epirubicin—breast cancer	6.69e-05	0.000269	CcSEcCtD
Dicyclomine—Dermatitis—Capecitabine—breast cancer	6.69e-05	0.000269	CcSEcCtD
Dicyclomine—Tachycardia—Doxorubicin—breast cancer	6.68e-05	0.000269	CcSEcCtD
Dicyclomine—Headache—Capecitabine—breast cancer	6.65e-05	0.000268	CcSEcCtD
Dicyclomine—Paraesthesia—Epirubicin—breast cancer	6.64e-05	0.000268	CcSEcCtD
Dicyclomine—Dyspnoea—Epirubicin—breast cancer	6.6e-05	0.000266	CcSEcCtD
Dicyclomine—Somnolence—Epirubicin—breast cancer	6.58e-05	0.000265	CcSEcCtD
Dicyclomine—Anorexia—Doxorubicin—breast cancer	6.53e-05	0.000263	CcSEcCtD
Dicyclomine—Nausea—Docetaxel—breast cancer	6.52e-05	0.000262	CcSEcCtD
Dicyclomine—Feeling abnormal—Methotrexate—breast cancer	6.52e-05	0.000262	CcSEcCtD
Dicyclomine—Dyspepsia—Epirubicin—breast cancer	6.51e-05	0.000262	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Methotrexate—breast cancer	6.47e-05	0.00026	CcSEcCtD
Dicyclomine—Decreased appetite—Epirubicin—breast cancer	6.43e-05	0.000259	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Epirubicin—breast cancer	6.39e-05	0.000257	CcSEcCtD
Dicyclomine—Fatigue—Epirubicin—breast cancer	6.38e-05	0.000257	CcSEcCtD
Dicyclomine—Pain—Epirubicin—breast cancer	6.33e-05	0.000255	CcSEcCtD
Dicyclomine—Constipation—Epirubicin—breast cancer	6.33e-05	0.000255	CcSEcCtD
Dicyclomine—Nausea—Capecitabine—breast cancer	6.31e-05	0.000254	CcSEcCtD
Dicyclomine—Urticaria—Methotrexate—breast cancer	6.28e-05	0.000253	CcSEcCtD
Dicyclomine—Abdominal pain—Methotrexate—breast cancer	6.25e-05	0.000252	CcSEcCtD
Dicyclomine—Insomnia—Doxorubicin—breast cancer	6.19e-05	0.000249	CcSEcCtD
Dicyclomine—Paraesthesia—Doxorubicin—breast cancer	6.15e-05	0.000248	CcSEcCtD
Dicyclomine—Dyspnoea—Doxorubicin—breast cancer	6.1e-05	0.000246	CcSEcCtD
Dicyclomine—Feeling abnormal—Epirubicin—breast cancer	6.1e-05	0.000246	CcSEcCtD
Dicyclomine—Somnolence—Doxorubicin—breast cancer	6.09e-05	0.000245	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Epirubicin—breast cancer	6.05e-05	0.000244	CcSEcCtD
Dicyclomine—Dyspepsia—Doxorubicin—breast cancer	6.03e-05	0.000243	CcSEcCtD
Dicyclomine—Decreased appetite—Doxorubicin—breast cancer	5.95e-05	0.00024	CcSEcCtD
Dicyclomine—Gastrointestinal disorder—Doxorubicin—breast cancer	5.91e-05	0.000238	CcSEcCtD
Dicyclomine—Fatigue—Doxorubicin—breast cancer	5.9e-05	0.000238	CcSEcCtD
Dicyclomine—Urticaria—Epirubicin—breast cancer	5.88e-05	0.000237	CcSEcCtD
Dicyclomine—Constipation—Doxorubicin—breast cancer	5.85e-05	0.000236	CcSEcCtD
Dicyclomine—Pain—Doxorubicin—breast cancer	5.85e-05	0.000236	CcSEcCtD
Dicyclomine—Abdominal pain—Epirubicin—breast cancer	5.85e-05	0.000236	CcSEcCtD
Dicyclomine—Hypersensitivity—Methotrexate—breast cancer	5.83e-05	0.000235	CcSEcCtD
Dicyclomine—Asthenia—Methotrexate—breast cancer	5.67e-05	0.000228	CcSEcCtD
Dicyclomine—Feeling abnormal—Doxorubicin—breast cancer	5.64e-05	0.000227	CcSEcCtD
Dicyclomine—Gastrointestinal pain—Doxorubicin—breast cancer	5.6e-05	0.000225	CcSEcCtD
Dicyclomine—Pruritus—Methotrexate—breast cancer	5.59e-05	0.000225	CcSEcCtD
Dicyclomine—Hypersensitivity—Epirubicin—breast cancer	5.45e-05	0.00022	CcSEcCtD
Dicyclomine—Urticaria—Doxorubicin—breast cancer	5.44e-05	0.000219	CcSEcCtD
Dicyclomine—Abdominal pain—Doxorubicin—breast cancer	5.41e-05	0.000218	CcSEcCtD
Dicyclomine—Asthenia—Epirubicin—breast cancer	5.31e-05	0.000214	CcSEcCtD
Dicyclomine—Pruritus—Epirubicin—breast cancer	5.24e-05	0.000211	CcSEcCtD
Dicyclomine—Dizziness—Methotrexate—breast cancer	5.23e-05	0.000211	CcSEcCtD
Dicyclomine—Hypersensitivity—Doxorubicin—breast cancer	5.04e-05	0.000203	CcSEcCtD
Dicyclomine—Vomiting—Methotrexate—breast cancer	5.03e-05	0.000202	CcSEcCtD
Dicyclomine—Rash—Methotrexate—breast cancer	4.99e-05	0.000201	CcSEcCtD
Dicyclomine—Dermatitis—Methotrexate—breast cancer	4.98e-05	0.000201	CcSEcCtD
Dicyclomine—Headache—Methotrexate—breast cancer	4.95e-05	0.000199	CcSEcCtD
Dicyclomine—Asthenia—Doxorubicin—breast cancer	4.91e-05	0.000198	CcSEcCtD
Dicyclomine—Dizziness—Epirubicin—breast cancer	4.89e-05	0.000197	CcSEcCtD
Dicyclomine—Pruritus—Doxorubicin—breast cancer	4.84e-05	0.000195	CcSEcCtD
Dicyclomine—Vomiting—Epirubicin—breast cancer	4.7e-05	0.000189	CcSEcCtD
Dicyclomine—Nausea—Methotrexate—breast cancer	4.7e-05	0.000189	CcSEcCtD
Dicyclomine—Rash—Epirubicin—breast cancer	4.67e-05	0.000188	CcSEcCtD
Dicyclomine—Dermatitis—Epirubicin—breast cancer	4.66e-05	0.000188	CcSEcCtD
Dicyclomine—Headache—Epirubicin—breast cancer	4.64e-05	0.000187	CcSEcCtD
Dicyclomine—Dizziness—Doxorubicin—breast cancer	4.53e-05	0.000182	CcSEcCtD
Dicyclomine—Nausea—Epirubicin—breast cancer	4.4e-05	0.000177	CcSEcCtD
Dicyclomine—Vomiting—Doxorubicin—breast cancer	4.35e-05	0.000175	CcSEcCtD
Dicyclomine—Rash—Doxorubicin—breast cancer	4.32e-05	0.000174	CcSEcCtD
Dicyclomine—Dermatitis—Doxorubicin—breast cancer	4.31e-05	0.000174	CcSEcCtD
Dicyclomine—Headache—Doxorubicin—breast cancer	4.29e-05	0.000173	CcSEcCtD
Dicyclomine—Nausea—Doxorubicin—breast cancer	4.07e-05	0.000164	CcSEcCtD
Dicyclomine—CHRM3—Signaling Pathways—PLA2G4A—breast cancer	1.02e-05	0.000122	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NCOR1—breast cancer	1.02e-05	0.000122	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HES1—breast cancer	1.02e-05	0.000121	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CSF2—breast cancer	1.01e-05	0.000121	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGF1—breast cancer	1.01e-05	0.000121	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NCOR1—breast cancer	1.01e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PLA2G4A—breast cancer	1.01e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—RAF1—breast cancer	1.01e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGF1—breast cancer	1.01e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CSF2—breast cancer	1.01e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—RAF1—breast cancer	1.01e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NRG1—breast cancer	1e-05	0.00012	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NRG1—breast cancer	1e-05	0.000119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGF1—breast cancer	9.98e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CSF2—breast cancer	9.98e-06	0.000119	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ABCB1—breast cancer	9.97e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—H2AFX—breast cancer	9.96e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—IL2—breast cancer	9.96e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—RAF1—breast cancer	9.96e-06	0.000119	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—CAV1—breast cancer	9.94e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—H2AFX—breast cancer	9.93e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—IL2—breast cancer	9.93e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NRG1—breast cancer	9.91e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—E2F1—breast cancer	9.89e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—E2F1—breast cancer	9.86e-06	0.000118	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CB—breast cancer	9.85e-06	0.000117	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—H2AFX—breast cancer	9.83e-06	0.000117	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—IL2—breast cancer	9.83e-06	0.000117	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CB—breast cancer	9.82e-06	0.000117	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—TYMS—breast cancer	9.79e-06	0.000117	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—E2F1—breast cancer	9.77e-06	0.000116	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CB—breast cancer	9.72e-06	0.000116	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GSTM1—breast cancer	9.68e-06	0.000115	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—NCOR1—breast cancer	9.68e-06	0.000115	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PLA2G4A—breast cancer	9.68e-06	0.000115	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SPP1—breast cancer	9.5e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SPP1—breast cancer	9.47e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—CXCL8—breast cancer	9.46e-06	0.000113	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—CXCL8—breast cancer	9.43e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB3—breast cancer	9.4e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGFR2—breast cancer	9.39e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SPP1—breast cancer	9.38e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB3—breast cancer	9.37e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGFR2—breast cancer	9.36e-06	0.000112	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—CXCL8—breast cancer	9.34e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB3—breast cancer	9.28e-06	0.000111	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—GPX1—breast cancer	9.27e-06	0.000111	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGFR2—breast cancer	9.27e-06	0.00011	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ERCC2—breast cancer	9.1e-06	0.000109	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CG—breast cancer	9.05e-06	0.000108	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL2—breast cancer	9.04e-06	0.000108	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL2—breast cancer	9.01e-06	0.000107	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TERT—breast cancer	9.01e-06	0.000107	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TERT—breast cancer	8.98e-06	0.000107	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL2—breast cancer	8.93e-06	0.000106	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TERT—breast cancer	8.89e-06	0.000106	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FGFR1—breast cancer	8.75e-06	0.000104	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FGFR1—breast cancer	8.72e-06	0.000104	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FGFR1—breast cancer	8.64e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HIF1A—breast cancer	8.62e-06	0.000103	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HIF1A—breast cancer	8.59e-06	0.000102	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—MTHFR—breast cancer	8.56e-06	0.000102	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HIF1A—breast cancer	8.51e-06	0.000101	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—LEP—breast cancer	8.41e-06	0.0001	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—LEP—breast cancer	8.38e-06	0.0001	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CAV1—breast cancer	8.33e-06	9.94e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CAV1—breast cancer	8.31e-06	9.91e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—LEP—breast cancer	8.3e-06	9.9e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KDR—breast cancer	8.24e-06	9.83e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CAV1—breast cancer	8.23e-06	9.81e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KDR—breast cancer	8.21e-06	9.8e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KDR—breast cancer	8.13e-06	9.7e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ESR1—breast cancer	8.03e-06	9.58e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ESR1—breast cancer	8.01e-06	9.55e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CD—breast cancer	7.96e-06	9.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—FN1—breast cancer	7.93e-06	9.46e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ESR1—breast cancer	7.93e-06	9.45e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—FN1—breast cancer	7.91e-06	9.43e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—CAV1—breast cancer	7.89e-06	9.41e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—ALB—breast cancer	7.85e-06	9.36e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NFKBIA—breast cancer	7.84e-06	9.35e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—FN1—breast cancer	7.83e-06	9.34e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NFKBIA—breast cancer	7.81e-06	9.32e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOTCH1—breast cancer	7.76e-06	9.26e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOTCH1—breast cancer	7.74e-06	9.23e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NFKBIA—breast cancer	7.74e-06	9.23e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOTCH1—breast cancer	7.66e-06	9.14e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—APC—breast cancer	7.59e-06	9.05e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KIT—breast cancer	7.59e-06	9.05e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CG—breast cancer	7.59e-06	9.05e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KIT—breast cancer	7.57e-06	9.02e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CG—breast cancer	7.57e-06	9.02e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—APC—breast cancer	7.57e-06	9.02e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism of lipids and lipoproteins—PIK3CA—breast cancer	7.54e-06	8.99e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—NOS3—breast cancer	7.51e-06	8.96e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGF—breast cancer	7.5e-06	8.95e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CG—breast cancer	7.49e-06	8.94e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KIT—breast cancer	7.49e-06	8.94e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—APC—breast cancer	7.49e-06	8.94e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGF—breast cancer	7.48e-06	8.92e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGF—breast cancer	7.41e-06	8.83e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—MAPK3—breast cancer	7.27e-06	8.67e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—MAPK3—breast cancer	7.25e-06	8.64e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CG—breast cancer	7.19e-06	8.57e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—MAPK3—breast cancer	7.18e-06	8.56e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—BRAF—breast cancer	7.14e-06	8.51e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—BRAF—breast cancer	7.11e-06	8.48e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—BRAF—breast cancer	7.04e-06	8.4e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IGF1—breast cancer	6.95e-06	8.29e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT2—breast cancer	6.95e-06	8.28e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CB—breast cancer	6.93e-06	8.27e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IGF1—breast cancer	6.93e-06	8.26e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT2—breast cancer	6.92e-06	8.26e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—EGFR—breast cancer	6.92e-06	8.25e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—EGFR—breast cancer	6.89e-06	8.22e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTGS2—breast cancer	6.87e-06	8.19e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IGF1—breast cancer	6.86e-06	8.18e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT2—breast cancer	6.86e-06	8.18e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—EGFR—breast cancer	6.83e-06	8.14e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CD—breast cancer	6.67e-06	7.96e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CD—breast cancer	6.65e-06	7.93e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—PIK3CA—breast cancer	6.61e-06	7.88e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SERPINE1—breast cancer	6.6e-06	7.87e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—PIK3CA—breast cancer	6.59e-06	7.86e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CD—breast cancer	6.59e-06	7.86e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SERPINE1—breast cancer	6.58e-06	7.85e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—KRAS—breast cancer	6.53e-06	7.79e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—PIK3CA—breast cancer	6.53e-06	7.78e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SERPINE1—breast cancer	6.52e-06	7.77e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—KRAS—breast cancer	6.51e-06	7.77e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—KRAS—breast cancer	6.45e-06	7.69e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CD—breast cancer	6.32e-06	7.54e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—NOS3—breast cancer	6.3e-06	7.51e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—NOS3—breast cancer	6.28e-06	7.49e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—ALB—breast cancer	6.24e-06	7.44e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—NOS3—breast cancer	6.22e-06	7.42e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—PIK3CA—breast cancer	6e-06	7.16e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PTEN—breast cancer	5.99e-06	7.15e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—PIK3CA—breast cancer	5.98e-06	7.13e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MDM2—breast cancer	5.98e-06	7.13e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—NOS3—breast cancer	5.97e-06	7.12e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MDM2—breast cancer	5.96e-06	7.11e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RAF1—breast cancer	5.96e-06	7.1e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RAF1—breast cancer	5.94e-06	7.08e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—RELA—breast cancer	5.93e-06	7.07e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—PIK3CA—breast cancer	5.93e-06	7.07e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—RELA—breast cancer	5.91e-06	7.05e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MDM2—breast cancer	5.9e-06	7.04e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—ERBB2—breast cancer	5.89e-06	7.03e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RAF1—breast cancer	5.88e-06	7.01e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—ERBB2—breast cancer	5.88e-06	7.01e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—RELA—breast cancer	5.86e-06	6.98e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—ERBB2—breast cancer	5.82e-06	6.94e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MTOR—breast cancer	5.82e-06	6.94e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CB—breast cancer	5.82e-06	6.94e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CB—breast cancer	5.8e-06	6.91e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MTOR—breast cancer	5.8e-06	6.91e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MTOR—breast cancer	5.74e-06	6.85e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CB—breast cancer	5.74e-06	6.85e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CXCL8—breast cancer	5.59e-06	6.67e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CXCL8—breast cancer	5.57e-06	6.64e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—HRAS—breast cancer	5.55e-06	6.62e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—HRAS—breast cancer	5.54e-06	6.6e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CXCL8—breast cancer	5.52e-06	6.58e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CB—breast cancer	5.51e-06	6.57e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—HRAS—breast cancer	5.48e-06	6.54e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1B—breast cancer	5.46e-06	6.51e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTGS2—breast cancer	5.46e-06	6.51e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1B—breast cancer	5.44e-06	6.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—GPCR downstream signaling—AKT1—breast cancer	5.4e-06	6.44e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1B—breast cancer	5.39e-06	6.43e-05	CbGpPWpGaD
Dicyclomine—CHRM3—GPCR downstream signaling—AKT1—breast cancer	5.38e-06	6.42e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CASP3—breast cancer	5.35e-06	6.38e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL2—breast cancer	5.34e-06	6.37e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CASP3—breast cancer	5.33e-06	6.36e-05	CbGpPWpGaD
Dicyclomine—CHRM2—GPCR downstream signaling—AKT1—breast cancer	5.33e-06	6.36e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL2—breast cancer	5.33e-06	6.35e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—IL6—breast cancer	5.32e-06	6.34e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—IL6—breast cancer	5.3e-06	6.32e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CASP3—breast cancer	5.28e-06	6.3e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL2—breast cancer	5.27e-06	6.29e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—IL6—breast cancer	5.25e-06	6.26e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CCND1—breast cancer	5.21e-06	6.21e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—JUN—breast cancer	5.2e-06	6.2e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CCND1—breast cancer	5.19e-06	6.19e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—JUN—breast cancer	5.18e-06	6.18e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CTNNB1—breast cancer	5.16e-06	6.15e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CCND1—breast cancer	5.14e-06	6.13e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CTNNB1—breast cancer	5.14e-06	6.13e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—JUN—breast cancer	5.13e-06	6.12e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CTNNB1—breast cancer	5.09e-06	6.07e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MMP9—breast cancer	5.06e-06	6.03e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MMP9—breast cancer	5.04e-06	6.01e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—CDKN1A—breast cancer	5.04e-06	6.01e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PTEN—breast cancer	5.03e-06	5.99e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—CDKN1A—breast cancer	5.02e-06	5.99e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PTEN—breast cancer	5.01e-06	5.97e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MMP9—breast cancer	4.99e-06	5.95e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—CDKN1A—breast cancer	4.97e-06	5.93e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PTEN—breast cancer	4.96e-06	5.92e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK8—breast cancer	4.92e-06	5.86e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling by GPCR—AKT1—breast cancer	4.9e-06	5.85e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK8—breast cancer	4.9e-06	5.84e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling by GPCR—AKT1—breast cancer	4.89e-06	5.83e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK8—breast cancer	4.85e-06	5.79e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling by GPCR—AKT1—breast cancer	4.84e-06	5.77e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PTEN—breast cancer	4.76e-06	5.68e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—SRC—breast cancer	4.66e-06	5.56e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—SRC—breast cancer	4.65e-06	5.54e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—SRC—breast cancer	4.6e-06	5.49e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—VEGFA—breast cancer	4.54e-06	5.41e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—VEGFA—breast cancer	4.53e-06	5.4e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—STAT3—breast cancer	4.5e-06	5.36e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—VEGFA—breast cancer	4.48e-06	5.34e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—STAT3—breast cancer	4.48e-06	5.34e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—STAT3—breast cancer	4.44e-06	5.29e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MAPK3—breast cancer	4.29e-06	5.12e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MAPK3—breast cancer	4.28e-06	5.1e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MAPK3—breast cancer	4.24e-06	5.06e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—PIK3CA—breast cancer	4.23e-06	5.04e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—MYC—breast cancer	4.18e-06	4.98e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TGFB1—breast cancer	4.17e-06	4.97e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—MYC—breast cancer	4.16e-06	4.96e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TGFB1—breast cancer	4.15e-06	4.95e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—MYC—breast cancer	4.12e-06	4.92e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TGFB1—breast cancer	4.11e-06	4.9e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—EGFR—breast cancer	4.09e-06	4.87e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—EGFR—breast cancer	4.07e-06	4.86e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—EGFR—breast cancer	4.03e-06	4.81e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—KRAS—breast cancer	3.86e-06	4.6e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—KRAS—breast cancer	3.85e-06	4.59e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—KRAS—breast cancer	3.81e-06	4.54e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—PIK3CA—breast cancer	3.55e-06	4.23e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—PIK3CA—breast cancer	3.53e-06	4.21e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—PIK3CA—breast cancer	3.5e-06	4.17e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Metabolism—AKT1—breast cancer	3.45e-06	4.12e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—TP53—breast cancer	3.43e-06	4.09e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—TP53—breast cancer	3.42e-06	4.08e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—TP53—breast cancer	3.39e-06	4.04e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—PIK3CA—breast cancer	3.36e-06	4e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—HRAS—breast cancer	3.28e-06	3.91e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—HRAS—breast cancer	3.27e-06	3.9e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—HRAS—breast cancer	3.24e-06	3.86e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—IL6—breast cancer	3.14e-06	3.74e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—IL6—breast cancer	3.13e-06	3.73e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—IL6—breast cancer	3.1e-06	3.7e-05	CbGpPWpGaD
Dicyclomine—CHRM1—Signaling Pathways—AKT1—breast cancer	2.9e-06	3.45e-05	CbGpPWpGaD
Dicyclomine—CHRM3—Signaling Pathways—AKT1—breast cancer	2.89e-06	3.44e-05	CbGpPWpGaD
Dicyclomine—CHRM2—Signaling Pathways—AKT1—breast cancer	2.86e-06	3.41e-05	CbGpPWpGaD
Dicyclomine—CYP1A1—Metabolism—AKT1—breast cancer	2.74e-06	3.27e-05	CbGpPWpGaD
